HC Wainwright Analysts Increase Earnings Estimates for ESPR

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Stock analysts at HC Wainwright boosted their Q2 2025 earnings per share (EPS) estimates for Esperion Therapeutics in a research report issued on Tuesday, June 17th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will post earnings per share of ($0.18) for the quarter, up from their prior estimate of ($0.19). HC Wainwright has a "Buy" rating and a $16.00 price objective on the stock. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Esperion Therapeutics' Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.55) EPS.

A number of other research analysts have also recently weighed in on the company. The Goldman Sachs Group dropped their price target on Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating for the company in a research report on Thursday, April 17th. Needham & Company LLC dropped their price target on Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $7.00.

Esperion Therapeutics Trading Down 2.7%

Shares of ESPR stock traded down $0.03 during mid-day trading on Thursday, reaching $1.07. The stock had a trading volume of 5,147,603 shares, compared to its average volume of 5,181,044. Esperion Therapeutics has a 12-month low of $0.69 and a 12-month high of $3.94. The company has a market cap of $212.07 million, a P/E ratio of -1.34 and a beta of 0.67. The business has a 50-day simple moving average of $0.96 and a 200 day simple moving average of $1.57.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.03). Esperion Therapeutics had a negative net margin of 59.03% and a negative return on equity of 0.91%. The firm had revenue of $65.00 million during the quarter, compared to analysts' expectations of $54.97 million.

Institutional Trading of Esperion Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jones Financial Companies Lllp purchased a new stake in Esperion Therapeutics in the 1st quarter valued at about $278,000. Graham Capital Management L.P. grew its holdings in Esperion Therapeutics by 153.5% in the 1st quarter. Graham Capital Management L.P. now owns 487,735 shares of the biopharmaceutical company's stock valued at $702,000 after buying an additional 295,320 shares during the period. State of Wyoming grew its holdings in Esperion Therapeutics by 93.8% in the 1st quarter. State of Wyoming now owns 89,936 shares of the biopharmaceutical company's stock valued at $130,000 after buying an additional 43,526 shares during the period. CW Advisors LLC purchased a new stake in Esperion Therapeutics in the 1st quarter valued at about $74,000. Finally, Summit Financial LLC grew its holdings in Esperion Therapeutics by 40.1% in the 1st quarter. Summit Financial LLC now owns 65,194 shares of the biopharmaceutical company's stock valued at $94,000 after buying an additional 18,666 shares during the period. Hedge funds and other institutional investors own 47.39% of the company's stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.